Atosiban treatment for uterine hyperactivity during active labor: a pilot study.
A preliminary assessment of the ability of Atosiban to alleviate uterine hyperactivity during active labor. Fifteen consecutive women with uterine hyperactivity during active labor were included in this prospective observational study. Atosiban was given as a single or repeated intravenous bolus dose (6.75 mg in 0.9 mL NaCl solution) if hyperactivity was not alleviated within 5 minutes with "intrauterine resuscitation" measures. Alleviation of uterine activity was achieved in 14 out of 15 cases and was almost immediate in the responders. Alleviation of accompanying fetal heart rate abnormalities was achieved in 13 out of 14 cases. In 7 of 15 women a cesarean section was performed, eventually. Atosiban was well tolerated by all women and no side effects were noted. There were no 5 minutes Apgar scores of less than 7. There were no cases of neonatal asphyxia or neonatal mortality. Atosiban may be an effective treatment of uterine hyperactivity during active labor.